Alnylam Pharmaceuticals announces exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNA Interference therapeutics for infectious diseases.
Mathew Shanley
Advertisement
Articles by Mathew Shanley
Advertisement
Latest Updated Articles
Strategic Alliance Formed to Advance RNAi Therapeutics for Infectious DiseasesPublished: October 24th 2017 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients
2
Developing the Next Generation of Rifamycins for Non-TB Mycobacteria in a Post-Antibiotic Era
3
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
4
